Depakote ER in Borderline Personality Disorder

A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00222482

Enrollment

Registered

2005-09-22

Start date

2003-03-31

Completion date

2005-09-30

Last updated

2007-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Personality Disorder

Keywords

Borderline Personality Disorder

Brief summary

This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

Interventions

DRUGDepakote ER

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

21 Years to 55 Years

Healthy volunteers

Inclusion criteria

Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion criteria

Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol. \-

Design outcomes

Primary

Measure	Time frame
Symptom Checklist 90	—

Secondary

Measure	Time frame
Barratt Impulsivity Scale	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026